Heidi L. Wagner, J.D.
Heidi L. Wagner, J.D., is a senior biotechnology executive focused with an established expertise in health policy, pricing and reimbursement and patient advocacy. Ms. Wagner most recently headed the Government Affairs function at Global Blood Therapeutics (GBT), a South San Francisco-based biopharmaceutical company focused on developing therapies for sickle cell disease. Prior to GBT, Wagner held senior positions at Alexion, Inc., where she built and led the global government affairs function, as well as Genentech, Inc., and has also consulted for a variety of health plans, biopharmaceutical and other health care-related companies. Wagner currently sits on the Board of Wave Life Sciences, Inc., and is a University of Colorado Foundation Trustee.
Wagner has more than 25 years of experience in health care legislative and regulatory policy issues. Her policy expertise broadly encompasses issues relating to biotechnology/pharmaceuticals and public payer policy. She has led numerous federal legislative/regulatory strategic efforts relating to, among other issues, Medicare payment policy, follow-on biologics/biosimilars and HIPAA/health privacy; and advises regularly on the commercial implications of such federal policy and political initiatives.
Wagner received a bachelor's degree in journalism and mass communication from the University of Colorado in Boulder, and a law degree from the George Mason University School of Law in Virginia.
Wagner is a member of the AKF Board of Trustees, and serves as Vice-Chair of the Audit & Compliance Committee and member of the Public Policy Committee.